Summary
Fifty-eight patients, aged 48–87 years, with impaired renal function and mean initial creatinine clearance of 52.1 mls/min were recruited to a 12-week open study of tenoxicam 20 mg/day for osteoarthrosis or rheumatoid arthritis. Renal function was mea sured before and after a brief run-in period when patients discontinued all nonsteroidal anti-inflammatory drugs, taking paracetamol alone, prior to monthly monitoring thereafter. Fifty-four% of patients completed the study, the others being withdrawn from lack of efficacy (17%), adverse events (24%) or both (5%). During the run-in period the mean creatinine clearance of 28 patients completing the trial improved to 64.7 mls/min and then dropped to 57.9 mls/min during the course of 12 weeks treatment with tenoxicam. Serial analysis of haematological and biochemical safety parameters showed no drug-induced change of significance. Twenty-three% of patients felt worse and 45% better at the end of treatment. Seventeen patients withdrew because of adverse events. These were normally gastrointestinal and always unrelated to further deterioration in renal function. Tenoxicam, 20 mg/day, can be given safely for a period of at least three months in patients with mild or moderate renal impairment.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Roche Products Limited 1987. Data on File.
Horber, F.F., Guentert, T.W., Weidekamm, E., Heizmann, P., Descoeudres, C., Frey, F.J. Pharmacokinetics of tenoxicam in patients with impaired renal function. Eur J Clin Pharm 1986, 29, 697–701.
Burry, H.C., Dieppe, P.A. Apparent reduction of endogenous creatinine clearance by salicylate treatment. Br Med J 1976, 2, 16–17.
Adams, D.H., Michael, J., Bacon, P.A., Howie, A.J., McConkey, B., Adu, D. Nonsteroidal anti-inflammatory drugs and renal failure. Lancet 1986, i, 57–59.
Unsworth, J., Sturman, S., Lunec, J., Blake, D.R. Renal impairment associated with nonsteroidal anti-inflammatory drugs. Ann Rheum Dis 1987, 46, 233–236.
Bird, H.A., Francis, J.R., le Gallez, P., Hill, J., Dixon, J.S., Allen, J.G., Wright, V. Single and multiple oral dose pharmacokinetics of tenoxicam in the elderly. Eur J Rheum Inflamm 1985, 8, 60–69.
Dixon, J.S., Bojar, R., Bird, H.A. Renal impairment in relation to nonsteroidal anti-inflammatory drugs. Ann Rheum Dis 1988, 47, 260–264.
Gow, P.J. Renal impairment associated with nonsteroidal anti-inflammatory drugs. Ann Rheum Dis 1987, 46, 877.
Brooks, P., Boutagy, J., McCredie, M., Forrest, M., Pei-Ling, L. Pharmacokinetics and effects of isoxicam on renal function in patients with renal insufficiency. III World Conference on Clinical Pharmacology and Therapeutics, Stockholm, Sweden. 1986, Abstract 88.
Turney, J., Cooper, E.H. Renal biochemistry in rheumatic disease. In: Biochemical Aspects of Rheumatic Diseases. Editors: Bird, H.A. Dixon, J.S. Baillières Clinical Rheumatology 2.1. Publ Baillière Tindall, London, Philadelphia, Sydney, Tokyo, Toronto. 1988. 233–258.
Gabriel, R. Time to scrap creatinine clearance ? Br Med J 1986, 293, 1119–1120.
Dixon, J.S., Bojar, R., Saunders, N. Is measurement ofβ 2 microglobulin worthwhile ? Br J Rheumatol 1988, 27, 80–81.
Dieppe, P.A., Doyle, D.V., Burry, H.C. Renal damage during treatment of anti-rheumatic drugs. Br Med J 1978, 3, p. 664.
Bird, H.A., Yu, H., Cooper, E.H. Renal proximal tubular dysfunction in patients with rheumatic diseases. Br Med J 1984, 288, 1044–1045.
Richards, I.M., Fraser, S.M., Capell, H.A., Fox, J.G., Bolton-Jones, J.M. A survey of renal function in out-patients with rheumatoid arthritis. Clin Rheumatol 1988, 7, 267–271.
Ralston, S.H., Caine, N., Richards, I., O'Reilly, D., Sturrock, R.D., Capell, H.A. Screen for proteinuria in a rheumatology clinic: comparison of dipstick testing, 24-hour urine quantitative proteinuria and protein/creatinine ratio in random urine samples. Ann Rheum Dis 1988, 47, 759–763.
Kelly, C.A., Mooney, P., Horden, L.D., Griffiths, I.D. Haematuria in rheumatoid arthritis — A follow-up study. Br J Rheumatol 1988, 27, Suppl. 1, 40.
Hartmann, D., Kleinbloesem, C.H., Lucker, P.W., Vetter, G. Study on the possible interaction between tenoxicam and furosemide. Drug Res 1987, 37, 1072–1076.
Favre, L., Glasson, P.H., Riondel, A., Vallotton, M.B. Interaction of diuretics and nonsteroidal anti-inflammatory drugs in man. Clin Science 1983, 64, 407–415.
Koopmans, P.P., Thien, T.H., Gribnau, F.W.J. Influence on nonsteroidal anti-inflammatory drugs on diuretic treatment of mild to moderate essential hypertension. Br Med J 1984, 289, 1492–1494.
Wong, D.J., Lamki, L., Spence, J.D., Freeman, D., McDonald, I.W.D. Effect of nonsteroidal anti-inflammatory drugs on control of hypertension by beta-blockers and diuretics. Lancet 1986, i, 997–1001.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bird, H.A., Clarke, A.K., Fowler, P.D. et al. An assessment of tenoxicam, a nonsteroidal anti-inflammatory drug of long half-life, in patients with impaired renal function suffering from osteoarthritis or rheumatoid arthritis. Clin Rheumatol 8, 453–460 (1989). https://doi.org/10.1007/BF02032096
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02032096